NCT06930625

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-11-26Est. Completion: 2028-06

Enrollment target: 119 participants

Locations

Cedars Sinai Medical Center, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
Harvard Medical School, Boston, Massachusetts, United States
Washington University-School of Medicine, St Louis, Missouri, United States
Palm Research Center Inc, Las Vegas, Nevada, United States
NYU Grossman School of Medicine, New York, New York, United States
The Cleveland Clinic, Cleveland, Ohio, United States
The Ohio State University, Columbus, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Medical University Graz, Graz, Austria
Medizinische Universitaet Wien - Division of Endocrinology and Metabolism, Vienna, Austria
UZ Gent, Ghent, Belgium
Hospital Medical Center L2, Brasília, Brazil
CETI - Centro de Estudos em Terapias Inovadoras, Curitiba, Brazil
Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, Brazil

PanhypopituitarismGigantism/AcromegalyProlactinomaCushing Disease

There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are…

Bethesda, United States

Acromegaly Due to Pituitary AdenomaHyperglycemiaKetogenic DietStandard Care Control

Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficie…

Leiden, NetherlandsEst. completion Dec 31, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.